Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin

Circulation: Cardiovascular Quality and Outcomes

Volumn 5, Issue 4, 2012, Pages 472-479

  Lee, Soyon ^a,b   Anglade, Moise W ^c   Meng, Joy ^a   Hagstrom, Kelly ^a   Kluger, Jeffrey ^b   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c Center for Advanced Cardiovascular Medicine   (United States)

Author keywords

Anticoagulants; Aspirin; Atrial fibrillation; Cost effectiveness; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; WARFARIN;

AGED; ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOLLOW UP; HEALTH ECONOMICS; HEART ATRIUM FIBRILLATION; HUMAN; MEDICARE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STROKE;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DRUG COSTS; HEMORRHAGE; HUMANS; MARKOV CHAINS; MEDICARE; MODELS, ECONOMIC; PRIMARY PREVENTION; PROBABILITY; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 84864625439     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.112.965251     Document Type: Article

References (40)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
2. Go AS, Fang MC, Singer DE. Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis. 2005;48:108-124.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:938-988.
4. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
5. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
6. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287-2292.
7. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
8. Thomson R, Parkin D, Ecceles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 2000;355:956-962.
9. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
10. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Maclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies Of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695-703.
11. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
12. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449-1457.
13. Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. www.cearegistry.org. Accessed August 25, 2011.
14. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;174:1839-1845.
15. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706.
16. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2009;2:429-436.
17. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
19. Agency for Healthcare Research and Quality. 2003 Nationwide Inpatient Sample. Healthcare Cost and Utilization Project: Rockville, MD; 2003.
20. Ariesen MJ, Claus SP, Rinkel GJE, Algra A. Risk factors for intracerebral hemorrhage in the general population. Stroke. 2003;34: 2060-2066.
21. Krumholz HM, Merrill AR, Schone EM, Schrenier GC, Chen J, Bradley EH, Wang Y, Wang Y, Lin Z, Straube BM, Rapp MT, Normand SL, Drye EE. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009;2:407-413.
22. United States Census Bureau. The 2011 Statistical Abstract. http://www.census.gov/compendia/statab/cats/births-deaths-marriages-divorces. html. Assessed July 22, 2011.
23. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
24. Boehringer Ingelheim. Boehringer Ingelheim's Pradaxa available in US pharmacies starting Wednesday, November 3 [press release]. http://www. prnewswire.com/news-releases/boehringer-ingelheims-pradaxa-available-in-us- pharmacies-starting-wednesday-november-3-106474818.html. November 1, 2010. Assessed July 22, 2011.
25. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality website; 2009. http://hcupnet.ahrq.gov. Assessed August 25, 2011.
26. Leibson CL, Hu T, Brown RD, Hass SL, O'Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after stoke: a population-based study. Neurology. 1996;46:861-869.
27. Holloway RG, Witter DM Jr, Lawton KB, Lipscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:854-860.
28. Matchar DB, Samsa GP. Secondary and Tertiary Prevention of Stroke: Patient Outcomes Research Team (PORT) Final Report: Phase 1. AHRQ publication No. 00-N001. Rockville, MD: Agency for Healthcare Research and Quality; 2000.
29. Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. Am Heart J. 2008;156: 698-705.
30. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J. 2001;141:727-734.
31. DRG Expert 2010. Salt Lake City, UT: Ingenix; 2009.
32. American Medical Association. CPT Code/Relative Value Search. AMA Coding Online website. https://catalog.ama-assn.org/Catalog/cpt/cpt-search.jsp?- requestid=782991. Accessed August 25, 2011.
33. United States Department of Labor. Consumer Price Index. Bureau of Labor Statistics website. http://www.bls.gov/cpi/. Accessed August 25, 2011.
34. Greenberg D, Winkelmayer WC, Neumann PJ. Prevailing judgments about society's willingness to pay for a QALY: do they vary by country? Have they changed over time? Abstr Value Health. 2006;9: A-60.
35. Grosse SD. Assessing cost-effectiveness in healthcare: history of the 50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165-178.
36. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641.
37. Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy. 2006;11:46-51.
38. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-2078.
39. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA III, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM; 2011 Writing Group Members, Fuster V, Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson SB, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann LS; 2006 Writing Committee Members, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;123:104-123.
40. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570.